Loading provider…
Loading provider…
Internal Medicine Physician in Tampa, FL
NPI: 1326257262Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get MD, MS Benjamin's Phone Numberphone_androidMobile
Get MD, MS Benjamin's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
FL State Medical License
FL State Medical License
2009 - 2026
PA State Medical License
2007 - 2010

American Board of Internal Medicine
Medical Oncology
Sidney Kimmel Medical College
jefferson.edu
Medical School
Until 2007
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General Hospital
Fellowship • Hematology and Medical Oncology
2010 - 2013
Sidney Kimmel Medical College at Thomas Jefferson University/TJUH
Residency • Internal Medicine
2007 - 2010
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 94 | 180 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 55 | 55 |
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Authors: Mei Tang
Publication Date: 2021-01
Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells.
The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer
Authors: Tawee Tanvetyanon, Scott Antonia
Journal: Expert Rev Anticancer Ther
Publication Date: 2016-08-22
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Intervention / Treatment: DRUG: Nivolumab, DRUG: Cyclophosphamide, DRUG: Fludarabine, BIOLOGICAL: Tumor-infiltrating Lymphocytes (TIL), OTHER: Tumor-infiltrating Lymphocyte Therapy, DRUG: Interleukin-2 (IL2)